DocumentsDate added
Case Report:-
*1Ramachandran Sudarshan,2Rajeshwari G.Annigeri,3Ali IM & 4G. Sree Vijayabala
Affiliation:-
1Senior Lecturer, Department of Oral Medicine and Radiology, Best Dental Science College, Ultra Nagar, Madurai-Chennai Highway, Madurai - 625 104,India.
2Professor and Head, Department of Oral Medicine and Radiology, College of Dental Sciences & Hospital, Davangere, Karnataka, India
3Professor, College of Dental Sciences & Hospital, Davangere, Karnataka, India
4Assistant Professor in Dentistry, ESIC Medical College and PGIMSR, KK Nagar, Ashok Pillar road, Chennai, India.
Abstract:
Radiographs are the real boon not only to substantiate the diagnosis but also for the unpredicted diagnosis of lesions. One such accidentally detected lesion was odontogenic keratocyst. They are characterized by aggressive clinical behavior and high recurrence rates. We report a case of male patient who had come with chief complaint of pain in the right lower back region past 2 days. So periapical radiograph of that region was taken which showed a large radiolucent area. To confirm the extent panoramic radiograph was taken which revealed the alarming extension of approximately from the midline to the distal of third molar. Further investigations were carried out for the confirmation of diagnosis. So enucleation along with extraction of the involved teeth was done.
Key Words: Odontogenic keratocyst; Keratocystic Odontogenic Tumour; hedgehog signaling pathway.
References:
1.Madras J, Lapointe H. Keratocystic Odontogenic Tumour: Reclassification of the Odontogenic Keratocyst from Cyst to Tumour. JCDA 2008;74(2):165.
2.Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press. WHO classification of tumours series 2005; 306.
3.Barreto DC, Bale AE, De Marco L, Gomez RS. Immunolocalization of PTCH protein in odontogenic cysts and tumors. J Dent Res 2002; 81:757-60.
4.Kumamoto H, Ohki K, Ooya K. Expression of Sonic hedgehog (SHH) signaling molecules in ameloblastomas. J Oral Pathol Med 2004; 33: 185-90.
5.Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-3.
6.Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 1996; 12: 85–7.
7.Kichi E, Enokiya Y, Muramatsu T, Hashimoto S, Inoue T, Abiko Y, Shimono M. Cell proliferation, apoptosis and apoptosis-related factors in odontogenic keratocysts and in dentigerous cysts. J Oral Pathol Med 2005; 34:280-6
8.de Paula AM, Carvalhais JN, Domingues MG, Barreto DC, Mesquita RA. Cell proliferation markers in the odontogenic keratocyst: effect of inflammation. J Oral Pathol Med. 2000; 29:477-82.
9.Li TJ, Browne RM, Matthews JB. Epithelial cell proliferation in odontogenic keratocysts: immunocytochemical study of Ki67 in simple, recurrent and basal cell naevus syndrome (BCNS)-associated lesions. J Oral Pathol Med 1995; 24:221-6
10.Li TJ, Browne RM, Matthews JB. Expression of epidermal growth factor receptors by odontogenic jaw cysts. Virchows Arch A Pathol Anat Histopathol 1993; 423: 137-44.
11.Kumamoto H. Molecular pathology of odontogenic tumors. J Oral Pathol Med. 2006; 35:65-74.
12.Li TJ, Browne RM, Matthews JB. Immunocytochemical expression of growth factors by odontogenic jaw cysts. Mol Pathol 1997; 50:21-7.
13.http://en.wikipedia.org/wiki/File:Sonic_hedgehog_pathway.png
14.Shear M and Speight PM (eds): Cysts of the oral and maxillofacial regions. 4th edition. Oxford, Blackwell Munksgaard 2007.
15.Reichart PA, Philipsen HP. Odontogenic tumors and allied lesions. London, UK: Quintessence Publishing 2004; 41-332.
16.Myoung H, Hong S P, Hong S-D et al. Odontogenic keratocyst : Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 328- 33.
17.Chiang Y-C, Chao p-Z, Yang T-H, Peng B-Y, Lee F-P. Transnasal endoscopic marsupialization for a large midline maxillary odontogenic keratocyst in a 6-year-old child. Int J Pediatr Otorhinolaryngol Extra 2006; 1: 41-4.
18.Haring J I, Van Dis M L . Odontogenic keratocysts: A clinical, radiographic, and histopathologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1988; 66:145-53.
19.Chirapathomsakul D, Sastravaha P, Jansisyanont P. A review of odontogenic keratocysts and the behavior of recurrences. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jan 2006;101(1):5-9; discussion 10.
20.Philipsen HP. Keratocystic odontogenic tumor. In: Barnes L, Eveson JW, Reichart PA, Sidransky D, eds. World Health Organization Classification of Tumours: Pathology and Genetics Head and Neck Tumours. Lyon, France: IARC Press; 2005:306-7.
21.Odontogenic keratocyst. In: Sciubba JJ, Fantasia JE, Kahn LB, eds. Atlas of Tumor Pathology: Tumors and Cysts of the Jaw. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1999:34-40.
22.Mozaffari E, Marmor DS, Alawi F. Odontogenic keratocyst with a misleading clinical and radiologic appearance. Quintessence Int. Nov-Dec 2007;38(10):837-41.
23.http://emedicine.medscape.com/article/1731868-overview#showall
24.Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:36.
25.Zhang L, Sun ZJ, Zhao YF, Bian Z, Fan MW, Chen Z. Inhibition of SHH signaling pathway: molecular treatment strategy of odontogenic keratocyst. Med Hypotheses 2006; 67: 1242-4.
26.Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003; 100: 4616-21.
27.Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406:1005-9
28.Ogata S, Kubota Y, Yamashiro T, Takeuchi H, Ninomiya T, Suyama Y, Shirasuna K. Signaling pathways regulating IL-1alpha-induced COX-2 expression. J Dent Res 2007; 86: 186-91
29.http://www.chemicalforums.com/index.php?topic=51563.0.
Article citation:-
Sudarshan Ramachandran,Annigeri Rajeshwari G, IM Ali & Vijayabala Sree G. Odontogenic keratocyst - A silent tumor. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1292-1298. Available at http://www.jpbms.info.
Copyright © 2013 Sudarshan Ramachandran. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article:-
*1Abhishek Singh Nayyar,2Mubeen Khan,3G.T.Subhas.
Affiliation:-
1Assistant Professor, Department of Oral Medicine and Radiology, Saraswati-Dhanwantari Dental College and Hospital, Parbhani, Maharashtra, India.
2Professor and Head, Department of Oral Medicine and Radiology, Government Dental College and Research Institute, Bangalore, Karnataka, India.
3Professor and Head, Department of Neurology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
Author’s contributions-All authors contributed equally to this paper.
Abstract:
Epilepsy is described as a chronic neurological disorder characterized by recurrent seizures of cerebral origin, presenting with episodes of sensory, motor or autonomic phenomenon with or, without loss of consciousness. Despite tremendous advances in the understanding regarding the diagnosis and management of epilepsy, phenytoin still remains the drug of choice in an effective and safer long term management of this disorder. The long term administration of phenytoin, however, has been seen to lead to a number of adverse effects including tremendous fall in the levels of folic acid leading to the onset of several related disorders, most prominently megaloblastic anemias. On the other hand, folates administered at pharmacological doses have been blamed for a decrease in the concentration of phenytoin which is severe enough to precipitate seizures. However, the use of folates as adjuvant to the routine anti-epileptic therapy to overcome such effects requires further evaluation before coming to a conclusion.
Key words: Epilepsy; chronic neurological disorder; megaloblastic anemias; phenytoin.
References:
1.Sridharan R. Epidemiology of epilepsy. Current Science 2002;82:664-670.Link
2.Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631-6. Pubmed
3.Blume W, Lüders H, Mizrahi E, et al.Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001;42:1212-8.Pubmed
4.Sridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631-6. Pubmed
5. Radhakrishnan K, Pandian JD, Santhoshkumar T, et al. Prevalence, knowledge, attitude and practice of epilepsy in Kerala, South India. Epilepsia. 2000;41(8):1027–35.Pubmed
6. POND DA, BIDWELL BH, STEIN L. A survey of epilepsy in fourteen general practices. I. Demographic and medical data. Psychiatr Neurol Neurochir. 1960 Jul-Aug;63:217–236. 7.Pubmed
8. Bird, A. V., Heinz, H. J. and Klintwork, S., Epilepsia , 1962, 3 , 175–187.
9. Sato, S.,Clin. Neurol. (Tokyo), 1964; 4:313–24.
10.Juul-Jensen P, Foldspang A: Natural history of epileptic seizures. Epilepsia 1983;24:297-312.Scopus
11. Granieri, E., Rosati, G., Tola, R., Pavoni, M., Paolino, E.,Pinna, L. and Monetti, V. C.,ibid 1983;24:502–14.Link
12.Li, S. C.,Schoenberg, B. S., Chun-Cheng, W.,Xueming-Ming, C., Shu-Shun, Z. and Bolis, C. L.,ibid,1985;26:391–4.Link
13.Haerer AF, Anderson DW, Schoenberg BS. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia. 1986 Jan-Feb;27(1):66-75.Pubmed
14. Osuntokun BO, Adeuja AOG, Noltidge VA (1987). Prevalence of epilepsies in the Nigerian Africans: A Community based study. Epilepsia 28: 272-9.Pubmed
15.Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991;32:429–45.Pubmed
16.Aziz H, Guvener A, Akhtar SW, Hasan K Z. Comparative epidemiology of epilepsy in Pakistan and Turkey: population-based studies using identical protocols IBID 1997;38:716-22.Pubmed
17.Mani KS, Geeta R, Srinivas HV, et al. The Yelandur study: A community based approach to epilepsy in rural south India: Epidemiological aspects. Seizure 1998;7:281-8.Pubmed
18.Mani KS. Epidemiology of epilepsy in Karnataka, India. Neurosci Today 1997;1:167-74.
19.Cockerell OC, Shorvon SD. (eds) Epilepsy Current Concepts, Current Medical Literature Ltd, London, 1996;1-13.Link
20.Placencia M, Shorvon SD, Paredes V, et al. Epileptic seizures in an Andean region of Ecuador. Incidence and prevalence and regional variation1992;115:771-82.Pubmed
21.Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-468.Pubmed
22.Trost LF, Wender RC, Suter CC, et al. Management of epilepsy in adults: Treatment guidelines. Postgraduate Medicine 2005;118:29-33. Pubmed
23.Eadie MJ, Bladin PF (2001). "The interpretation of the epileptic process". A Disease Once Sacred: A History of the Medical Understanding of Epilepsy. London: John Libbey. p. 80. ISBN 0-86196-607-4. Retrieved 2013-05-04.Link
24.Dreyfus Jack (1998). A Remarkable Medicine Has Been Overlooked: Including an Autobiography and the Clinical Section of the Broad Range of Use of Phenytoin. Continuum International Publishing Group. ISBN 0-8264-1069-3.
25.Elinor Ware. The Chemistry of the Hydantoins.Chem Rev 1950;46:403-470.
26.Urech, Ann., 165, 99 (1873).PUBS.ACS
27.Organic Syntheses, Coll. Vol. 3, p.323 (1955); Vol. 20, p.42 (1940). Link
28.Bucherer and Steiner, J. prakt. Chem., 140, 291 (1934).Link
29.Bergs, Ger. pat. 566,094 (1929) [C. A., 27, 1001 (1933)].Link
30.Biltz H. Constitution of the Products of the Interaction of Substituted Carbamides on Benzil and Certain New Methods for the Preparation of 5, 5-Diphenylhydantoin. 1908;41:1379-1393.Onlinelibrary.wiley.com
31.Merrit HH, Putman TH. Sodium diphenylhydantoinate in the treatment of convulsive disorders. J Am Med Assoc 1938;111:1068-73.
32.Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th ed. (New York: McGraw-Hill, 2001).
33.Harrison's Principles of Medicine. 15th edition.NLM
34.Silverstein LH, Garnick JJ, Szikman M, et al. Medication induced gingival enlargement: A clinical review. Gen Dent 1997;45:371-6.Pubmed
35.Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake.Proceedings of the National Academy of Sciences of the United States of America 2009;106:15424-19.Pubmed
36.Weinstein SJ. Null Association between Prostate Cancer and Serum Folate, Vitamin B6, Vitamin B12, and Homocysteine. Cancer Epidemiology, Biomarkers, & Prevention 2003;12:1271-2.Pubmed
37.Dietary Supplement Fact Sheet: Folate. Office of Dietary Supplements, National Institutes of Health http://ods.od.nih.gov/factsheets/folate.asp.Link
38.Lanska DJ. Historical aspects of the major neurological vitamin deficiency disorders: The water-soluble B vitamins. Handbook Clin Neurol 2009;95:445-76.Pubmed
39.Mitchell HK, Snell EE, Williams RJ. The concentration of folic acid. J Am ChemSoc 1941;63:2284.
40.Zittoun J. Anemias due to disorder of folate, vitamin B12 and trans-cobalamin metabolism. La Revue du praticien 1993;43:1358-63.Pubmed
41.http://www.healthlinkbc.ca/healthfiles/hfile68g.stm.
42.Kamen B. Folate and anti-folate pharmacology. Seminars in oncology 1997;24:S18-30-9.Pubmed
43.Figueiredo. Folic Acid and Risk or Prostate Cancer: Results from a Randomized Clinical Trial. 2009.Pubmed
44.Smith C, Lieberman M, Marks DB, et al. Marks' essential medical biochemistry Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-9340-8, 2007.
45.Berg MJ, Rivey MP, Vern BA, et al. Phenytoin and folic acid: individualized drug-drug interaction. Ther Drug Monit1983;5:395-399.Link
46.Ch'ien LT, Krumdieck CL, Scott C-WJ, et al. Harmful effect of mega-doses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug-treated epileptics. Am J ClinNutr1975;28:51-58.Pubmed
47.Reynolds EH. Effects of folic acid on the mental state and fit-frequency of drug-treated epileptic patients. The Lancet 1967;1:1086-1088.Pubmed
48.Furlanut M, Benetello P, Avogaro A, et al. Effects of folic acid on phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 1978;24:294-297.Pubmed
49.Gaby AR. Natural approaches to epilepsy. Altern Med Rev 2007;12:9-24.Pubmed
50.Mattson RH, Gallagher BB, Reynolds EH, et al. Folate therapy in epilepsy: A controlled study. Arch Neurol 1973;29:78-81.Pubmed
51.O’Hare J, O’Driscoll D, Duggan B, et al. Increase in seizure frequency following folic acid. J Ir Med Assoc 1979;72:241-2.
52.Seligmann H, Potasman I, Weller B, et al. Phenytoin-folic acid interaction: A lesson to be learnt. Clin Neuropharmacol 1999;22:226-31.Pubmed
53.Steinweg DL, Bentley ML. Seizures following reduction in phenytoin level after orally administered folic acid. Neurology 2005;64:1982.Pubmed
54.Guidolin L, Vignoli A, Canger R. Worsening in seizure frequency and severity in relation to folic acid administration. Eur J Neurol 1998;5:301-3.Pubmed
55.Hiilesmaa VK, Teramo K, Granstrom ML, et al. Serum folate concentrations during pregnancy in women with epilepsy: Relation to anti-epileptic drug concentration, number of seizures, and fetal outcome. Br Med J (Clin Res Ed) 1983;287:577-99.Pubmed
Article citation:-
Abhishek Singh Nayyar, Mubeen Khan, G.T.Subhas, Rownak Khandelwal, Rahul Anand & Mohammed Imran. Phenytoin, epilepsy and folic acid interactions: Inside out. Journal of Pharmaceutical and Biomedical Sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1432-1438.Available at http://www.jpbms.info
Copyright © 2013 Abhishek Singh Nayyar, Mubeen Khan, G.T.Subhas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
*1G.Bhawani,2Ashutosh Kumar,3KSN Murthy & 4Neera Kumari
Affiliation:-
1Associate professor, Department of pharmacology, GSL Medical College & hospital, Rajahmundry, India
2Chief Interventional Cardiologist, GSL medical College & hospital, Rajahmundry, India.
3Head of the department, Department of pharmacology, GSL Medical College & hospital, Rajahmundry, India.
4Assistant professor, Department of Physiology,SRI Krishna medical college, Muzzafarpur, India.
Author’s contributions-All authors contributed equally to this paper.
Abstract:
Aim of study: The present study was designed with the aim of elucidating whether there exists any association between significant QTcd ( QT interval dispersion) and occurrence of complications in patients of acute myocardial infarction(AMI).
Methods & results: 60 patients with AMI admitted in intensive cardiac care unit during the period march 2012 to October 2012 were enrolled following inclusion/exclusion criteria’s. Variations in the QTcd were calculated for the patients from the time of admission till the day of discharge at a fixed time per day. Association between QTcd in (msec) and the eight complications taken as end point for the study was established. The mean time and age of the study population was 8±3.19 hours, 59 years respectively. A total of 48 patients developed complications. QTcd was significantly higher with complications of ventricular tachyarrythmias (7/60,83.6±24.6, CI 95%), left ventricular failure ( 7/60,76.5±14.1, CI 95%) . QTcd was very high in patients with pos tinfarct angina (3/60,108±36.030) and cardiogenic shock (6/60, 96±26.01). The most common complication observed was A-V block with significant QTCd in (15/60 , 63.16±32.2) Sudden death within 48 hours of thrombolysis having very high QTcd even at the time of Admission was observed in (5/60, 99.5 ± 13.79 to 110.62 ± 19.34 ).
Conclusion: QTcd was significantly higher in patients who developed complications except those with pericardial effusion and thromboembolism. There was no significant co-relation between the location of MI, QTc dispersion and development of complications. QTc dispersion was significantly very high in those patients with sudden death even at the time of admission.
Finally QT and QTc dispersion at admission and during stay in hospital may be used as an important non-invasive marker for prediction of various complications of AMI.
Key words: Acute myocardial infarction; QT interval; QTc dispersion; myocardial infarction complications.
References:
1.Bulatao RA , Stephens PW. Global estimates and projections of mortality by cause:Population,Health and nutrition Department; World Bank, 1007;1992.
2.Gaziano JM, Ridker PM, Libby P. Primary and secondary prevention of coronary heart disease. In: Bonow RO, Mann DL, Zipes DP, Libby P,eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier;2011:chapter 49.
3.Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge,critical gaps and new approaches to drug development and patient management.Am Heart J.2002;144:769-81. Pubmed
4.Kautzner J, Malik M; QT dispersion and its clinical utility, PACE 20 1997 2625-40.
5.Statters D.J, Malik M, Ward D.E, Camm A.J; QT dispersion. problems of methodology and clinical significance, J Cardiovasc Electrophysiol 1994;5:672-685.Pubmed
6.Higham PD et al QT dispersion does reflect regional variation in ventricular recovery circulation 1992;86(suppl 1):392.
7.Hohnloser SH et al QT dispersion in the surface ECG as a parameter of increased electrical vulnerability in acute myocardial ischaemia Z kardiol 1993;82:678-82.Pubmed
8.Levine SJ, Shah M: Increased QT dispersion associated with ventricular tachyarrhythmias in first 48 hours of myocardial infarction. Journal of Noninvasive Cardiology 1997; 1:8–21.
9.Shah C.P, Thakur R.K, Reisdorff E.J, Lane E, Aufderheide T.P, Hayes O.W; QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center, Am Heart J 136 1998 496-8.Pubmed
10.Schwartz PJ, Wolf S: QT-interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978;57:1074-7. Pubmed
11.Glancy JM, Garrat CJ, de Bono DP dynamics of QT dispersion during myocardial infarction and ischaemic. Int .J .cardiology 1996 ; 57:55-60.Pubmed
12.Aitchison JD et al. time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation. A prospective study Heart (British cardiac society) 2000;84:504-8.Pubmed
13.Bodi V et al QT dispersion within the 1st 6months after an acute myocardial infarction: relationship with systolic function, left ventricular volume, infarct related artery status and clinical out come international journal of cardiology 2001;80(1):37-45.Pubmed
16.Kabakci G et al what is the optimal evaluation time of QT dispersion after acute myocardial infarction for the risk stratification. Angiology 2001;52(7)463-820.Pubmed
17.Perkiomaki JS, Koistinen MJ, YliMayry, Herikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrythmias after previous myocardial infarction.Amercardiol 1995;28:174-9.Pubmed
18.Bjorn W , Dale J effect of very early intravenous streptokinase infusion in patients with evolving myocardial infarction, Actor Med Scand 1998;223:15-8.Pubmed
Article citation:-
Bhawani G.,Kumar Ashutosh ,Murthy KSN, Kumari Neera. Study of QT interval dispersion in acute myocardial infarction and its relationship with complications. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1425-1431.Available at http://www.jpbms.info
Copyright © 2013 Bhawani G., Kumar Ashutosh, Murthy KSN, Kumari Neera K. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Shyamala Viswanathan, Anagha Krishnamoorthy and Thangaraju Nallamuthu*
Affiliation:-
Centre for Advanced Studies in Botany, University of Madras, Guindy Campus, Chennai- 600 025, India.
The name of the department(s) and institution(s) to which the work should be attributed:
Centre for Advanced Studies in Botany, University of Madras.
Author’s contributions: - All author contributed equally to this paper.
Abstract:
Objective: To evaluate the in vitro antioxidant and antiproliferative activity of Ulva lactuca, Chnoospora implexa, and Chondrococcus hornemanni.
Methods: Dried seaweeds of Methanol extract of Ulva lactuca, Chnoospora implexa, and Chondrococcus hornemanni. In vitro total phenol and total flavonoid content were tested for the three different seaweeds. Antioxidant activity was determined by DPPH assay and Ferric Reducing Antioxidant Power (FRAP) assay. Antiproliferative activity was determined by 3 (4, 5– dimethylthiazole – 2-Yl), 2, 5- diphenyltetrazolium bromide (MTT) assay to determine the specificity against human breast cancer cell line (MCF-7).
Results: The highest total phenolic content was observed in C. implexa (87.0±0.04 mg GAE/g) when compare with other two different seaweeds and the total flavonoid content had showed highest activity in C. hornemanni (63.9±0.12 mg QE/ g) when compare with other two seaweeds. In vitro antioxidant activity of brown and red seaweed showed higher activity in both the assays than green seaweed. The LC 50 (Lethal concentration) of three different seaweeds was observed at 125 µg/mL concentration of the extract. The data showed that these species are a potential source of compounds for the treatment of certain cancer diseases. Therefore, finding new antiproliferative agents with low side effects could be interesting.
KeyWords: Seaweeds, Total phenol, Total flavonoid, Antioxidant, Antiproliferative and MCF-7.
References:
1.Albano RM, Pavao MS, Mourao PA, Mulloy B. Structural studies of a sulfated L-galactan from styela plicata (Tunicate) analysis of the smith-degraded polysaccharide. Carbohydr Res, 1990: 208: 163-74.
2.Berlinck RG, Ogawa CA, Almeida AM, Sanchez MA, Malpezzi EL, Costa LV, Hajdu E, Freitas JC. Chemical and pharmacological characterization of halitoxin from Amphimedon viridis (Porifera) from the southeastern Brazilian coast. Comp Biochem Physiol Clin Pharmacol Toxicol Endocrinol; 1996: 115: 155-163.
3.Blois MS. Antioxidant determinations by the use of a stable free radical. Nature, 1958: 181: 1199-1200.
4.Cai Q, Rahn RO, Zhang R. Dietary flavonoids, quercetin, luteolin and genistein, reduce oxidative DNA damage and lipid peroxidation and quench free radicals. Cancer Lett., 1997: 119: 99-107.
5.Chandini SK, Ganesan P and Bhaskar N. In vitro activities of three selected brown seaweeds of India. Food Chemistry 2008:107: 707-13.
6.Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffery RJ, Morrow JD. Antioxidants reduce cycloxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res., 1998: 58: 2323-2327.
7. Devery R, Miller A, Stanton C. Conjugated linoleic acid and oxidative behavior in cancer cells. Biochem. Soc. Trans. 2001: 29: 341-4.
8.Duan XJ, Zhang WW, Li XM and Wang BG. Evaluation of antioxidant property of extract and fractions obtained from a red alga, Polysiphonia urceolata. Food Chemistry 2006: 95: 37-43.
9.Faulkner DJ. Marine natural products. Nat Prod Rep; 2000: 17: 7-55.
10.Harada H, Noro T, Kamei Y. Selective antitumor activity in vitro from marine algae from Japan coasts. Biol Pharm Bull; 1997: 20: 541-6.
11.Khaleafa AF, Kharboush MAM, Metwalli A, Mohsen AF and Serwi A. Antibiotic (fungicidal) action from of some seaweed. Botanica Mar., 1975:18: 163.
12.Kahkonen MP, Hopia AI, Vuorela HJ, Rauha J, Pihlaja K, Kujala ST, Heinonen M. Antioxidant activity of plant extracts containing phenolic compounds. J. Agric. Food Chem. 1999:47: 3954-62.
13.Kuda T, Kunii T, Goto H, Suzuki T and Yano T. Varieties of antioxidant and antibacterial properties of Ecklonia stolonifera and Ecklonia kurome products harvested and processed in the Noto peninsula, Japan. Food Chemistry 2007: 103: 900-5.
14.Ly BM, Buu NQ, Nhut ND, Thinh PD, Thi T, Van T. Studies on fucoidan and its production from Vietnamese brown sea weeds. A J Sci Tech Dev; 2005: 22: 371-80.
15.Mayer AMS, Gustafson KR. Marine pharmacology: Antitumor and cytotoxic compounds. Int J Cancer 2003; 105: 291-9.
16.Matsukawa R, Dubinsky Z, Kishimoto E, Masaki KFY and Takeuchi T. A comparison of screening methods for antioxidant activity in seaweeds. Journal of Applied Phycology 1997: 9: 29-35.
17.Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983: 65: 55-63.
18.Nagai T, Yukimoto T. Preparation and functional properties of beverages made from sea algae. Food Chem., 2003: 81: 327–32.
19.Noda K, Tanaka K, Yamada A, Ogata J, Tanaka H, Shogama Y. Simple assay for antitumor immunoactive glycoprotein derived from Chlorella vulgaris strain CK22 using ELISA. Phytother Res; 2002: 16: 581-5.
20.Noda H, Amano H, Arashima K, Nisizawa K. Antitumor activity of marine algae. Hydrobiologia; 1990: 204-205: 577-84.
21.Kerr RG, Baker BJ (1991). Marine sterols. Nat. Prod. Rep. 8: 465-497.
22.Ogawa A, Murakami C, Kamisuki S, Kurigama I, Yoshida H, Sugawara F, Mizushina Y. Pseudodeflectusin, a novel isochroman derivative from Aspergillus pseudodeflectus a parasite of the seaweed, Sargassum fusiforme, as a selective human cancer cytotoxin. Bioorg Med Chem Lett; 2004: 14: 3539- 43.
23.Oyaizu M. Studies on products of browning reactions: Antioxidative activities of products of browning reaction prepared from glucosamine. Jpn. J. Nutr., 1986: 44: 307-15.
24.Oza RM and Zaidi SH. A Revised Checklist of Indian Marine Algae. Central Salt and Marine Chemicals Research Institute, Bhavanagar, India, 2000: pp: 296.
25.Park YK, Koo MH, Ikegaki M, Contado JL. Comparison of the flavonoid aglycone contents of Apis mellifera propolis from various regions of Brazil. Arq. Biol. Technol., 1997: 40: 97-106.
26.Ross JA and Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects and safety. Annual Review of Nutrition 2002: 22: 19-34.
27.Tziveleka LA, Vagias C, Roussis V, Natural products with anti-HIV activity from marine organisms. Curr Top Med Chem; 2003: 3: 1512-35.
28.Sergediene E, Jonsson K, Szymusiak H, Tyrskowska B, Rietjens I, Cenas N. Pro-oxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure activity relationships. F.E.B.S. Lett., 1999: 462: 392-6.
29.Shimada K, Fujikawa K, Yahara K, Nakamura T. Antioxidative properties of xanthan on the autoxidation of soybean oil in cyclodextrin emulsion. J. Agric. Food Chem., 1992: 40: 945-8.
30.Singleton VL and Rossi JA. Colorimetry of Total Phenolics with phosphomolybdic–phosphotungstic acid reagents. Am. J. Enol. Viticult., 1965: 16: 144-58.
31.Wang H, Gao XD, Zhou GC, Cai L, Yao WB. In vitro and in vivo antioxidant activity of aqueous extract from Choerospondias axillaris fruit. Food Chem., 2008: 106: 888-95.
32.Wan-Jiang R, Hay ME, Fairchild CR, Prudhomme J, Le Roch K, Aalbersberg W, Kubanek J. Antineoplastic unsatturated fatty acids from Fijian macroalgae. Phytochemistry, 2008: 69: 2495-2500.
33.Wang T, Jónsdóttir R and Ólafsdóttir G. Total phenolic compounds, radical scavenging and metal chelation of extracts from Icelandic seaweeds. Food Chemistry 2009: 116: 240-8.
34.Williams R J, Spencer JP and Rice-Evans C. Flavonoids: Antioxidants or signalling molecules? Free Radical Biology and Medicine 2004: 36: 838-49.
35.Xu N, Fan X, Yan X, Tseng C. Screening marine algae from China for their antitumor activities. J Appl Phycol; 2004:16: 451-6.
36.Yamamoto I, Takahashi M, Tamura E, Maruyama H, Mori H. Antitumor activity of edible marine algae: Effect of crude fucoidan fractions prepared from edible brown seaweeds against L-1210 leukemia. Hydrobiologia; 1984: 116-7.
37.Yan XJ, Li XC, Zhou CX and Fan X. Prevention of fish oil rancidity by Phlorotannins from Sargassum kjellmanianum. Journal of Applied Phycology 1996: 8: 201-3.
38.Yen GC, Chen HY. Antioxidant activity of various tea extracts in relation to their antimutagenicity. J Agric Food Chem, 1995: 43: 27–32.
39.Yoo HD, Ketchum SO, France D, Bair K, Gerwick WH. Vidalenolone. A novel phenolic metabolite from the tropical red alga Vidalia sp. J Nat Prod; 2002: 65: 51-3.
40.Yu-Bin J, Shi-Yong G, Xiu-juan Z. Influence of Sargassum fusiforme polysaccharide on apoptosis of tumor cells. China J Materia Med; 2004: 29: 245-7.
41.Yvonne Yuan V, Natalie Walsh A. Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food and Chemical Toxicology 2006: 44 1144–50.
42.Zubia M, Fabre MS, Kerjean V, Le Lann K, Stiger-Pouvreau V, Fauchon M, Deslandes E (2009). Antioxidant and antitumor activities of some Phaeophyta from Brittany Coasts. Food Chem. 116: 693-701.
Article citation:-
Shyamala Viswanathan, Anagha Krishnamoorthy and Thangaraju Nallamuthu. In vitro antioxidant and antiproliferative activities of macro algae against MCF-7 cell line. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1413-1424. Available at http://www.jpbms.info.
Copyright © 2013 Rohan Shanmuganathan & Indra Devi Subramaniam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
*1Rugmini Kamalammal and 2Jisha Susan Babu
Author’s contributions-All authors contributed equally to this paper.
Abstract:
Bronchiolitis is one of the most common lower respiratory infections in infants. There is a wide variation in treatment of bronchiolitis in different institutions and hence there is a need for standardization of existing modalities of treatment.
Aims:- To compare the efficacy of nebulised salbutamol versus adrenaline in infants admitted with bronchiolitis.
Settings and Design:- Tertiary care hospital. Randomized double blind case control trial.
Methods and Material:- Thirty infants admitted with the clinical diagnosis of bronchiolitis were included in the study. Each child received periodic doses of either nebulised salbutamol (group I) or adrenaline (group 2) and were assessed with respect to heart rate, respiratory rate, SpO2 and Respiratory Distress Assessment Instrument (RDAI).
Statistical analysis:- Student t -test
Results: In the 42nd hour and 48th hour the respiratory rates in the adrenaline group showed significant reduction as compared with the salbutamol group. There was statistically significant improvement in oxygen saturation and RDAI in the salbutamol group, when compared to adrenaline group at the 42nd hour of admission and RDAI showed further improvement at 48 hours in the same group. There was no significant difference in the improvements in heart rates between the two groups.
Conclusions:- There is definitely a benefit in relieving respiratory distress and reducing oxygen requirement with both salbutamol and adrenaline and it is more after 42 hours of treatment. Salbutamol seems to be better in terms of reduced oxygen requirement and improved RDAI score but adrenaline is found to be good in reducing respiratory rate alone.
Key words: Bronchiolitis; salbutamol; adrenaline.
References:
1.Hall CB. Respiratory syncytial virus and parainfluenza virus. New Engl J Med. 2001; 344(25):1917-28.
2.Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus among children under two years of age in a defined geographical area. Arch Dis child 2003; 88 (12) :1065-9.
3.Pelletier AJ, Mansbach JM, Camargo CA Jr . Direct medical costs of bronchiolitis hospitaliza-tions in the United States. Pediatrics. 2006 ; 118(6):2418-23.
4.Bronchiolitis in children- a national clinical guideline Nov 2006 1.1 Scottish Intercollegiate Guidelines Network. , ISBN 1 (10) 905813 01 5, ISBN (13) 978 1 905813 01.
5.Nagakumar P, Doull I. Current therapy for bronchiolitis. Arch Dis Child. 2012; 97(9):827-30.
6.Green RJ, Zar HJ, Jeena PM, Madhi SA, Lewis H. South African guideline for the diagnosis, management and prevention of acute viral bronchiolitis in children. S Afr Med J. 2010 M; 100(5):320, 322-5.
7.L Bialy, M Smith, T Bourke, L Becker. The Cochrane Library and bronchiolitis: an umbrella review (pages 939–947) . Evidence-Based Child Health: A Cochrane Review Journal2006; 1(4): 939–47.
8.Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2006; 3: CD001262 Update in: Cochrane Database Syst Rev. 2010;(12):CD001266
9.Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011 ,15;(6):CD003123.
10.Kellner JD, Ohlsson A, Gadomski AM, Wang EEL. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis. Arch Pediatr Adolesc Med 1996; 150: 1166-72.
11.M S Ray and V Singh. Comparison of Nebulised adrenaline versus Nebulised Salbutamol in Wheeze Associated Respiratory Tract infection in Infant .Indian Padiatrics.2002; 39:12-22.
12. Lowell DI, Lister G, Von Koss, McCarthy. Wheezing in Infants: The response to adrenaline. Pediatrics. 1987; 79(6):939–45.
13.23. Sqn Ldr BM John, Sqn Ldr SK Patnaik, Col PL Prasad. Efficacy of nebulised epineph-rine versus salbutamol in hospitalised children with bronchiolitis Medical Journal Armed Forces India 2006; 62(4): 354–7.
14.Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V.Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis.J Pediatr. 1993; 122(1):145-51.
15.Hartling L, Wiebe N, Russell K, Patel H, Klassen TP.A meta-analysis of randomized con-trolled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med.2003 ;157(10):957-64.
16.Schindler M. Do bronchodilators have an effect on bronchiolitis, Crit Care. 2002; 6(2): 111–2.
17.Can D, Inan G, Yendur G, Oral R, Gunay I. Salbutamol or mist in acute bronchiolitis. Acta Paediatric Jpn. 1998; 40:252–5.
18.Kristjansson S, Loprup-Carlsen KC, Wennergren G, Strannegard IL, Carlsen KH. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. Arch Dis Childh. 1993; 69:650–4.
19.Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomized trial of salbutamol in acute bronchiolitis. J Pediatr. 1991; 118:807–11.
20.Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of adrenaline with salbutamol in the treatment of acute bronchiolitis. J Paediatric 1995; 126: 1004-7.
21.M R Modaressi, A Asadian, J Faghihinia, M Arashpour, F Mousavinasab. Comparison of Epinephrine to Salbutamol in Acute Bronchiolitis. Iran J Pediatr. 2012 June; 22(2): 241–4.
22.Langley JM, Smith MB, LeBlanc JC, Joudrey H, Ojah CR, Pianosi P. Racemic adrenaline compared to salbutamol in hospitalized young children with bronchiolitis. BMC Pediatrics 2005; 5:7.
Article citation:-
Rugmini Kamalammal and Jisha Susan Babu. Efficacy of nebulised adrenaline versus salbutamol in hospitalised children with bronchiolitis. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1407-1412.Available at http://www.jpbms.info
Copyright © 2013 Rugmini Kamalammal and Jisha Susan Babu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.